Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497341 | 1.00 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1RAB9A | |
| SCHEMBL27429376 | 0.85 | PPARG (0.53) | LMNAKMT2AALDH1A1KDM4EPPARG | |
| SCHEMBL1497361 | 0.85 | SLC22A6 (0.52) | LMNAALDH1A1KDM4EPPARGPPARA | |
| SCHEMBL25326213 | 0.85 | PPARG (0.53) | LMNAKMT2AALDH1A1KDM4EPPARG | |
| SCHEMBL1497359 | 0.85 | SLC22A6 (0.52) | LMNAALDH1A1KDM4EPPARGPPARA | |
| SCHEMBL21238173 | 0.83 | PPARG (0.56) | LMNAKMT2AALDH1A1KDM4EPPARG | |
| Succinic Acid SCHEMBL28205145 | 0.81 | EGLN1 (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL28100381 | 0.81 | EGLN1 (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC15A2 | |
| Succinic Acid SCHEMBL28844915 | 0.80 | EGLN1 (0.64) | LMNAEGLN1ALKBH5SUCNR1SLC15A2 | |
| SCHEMBL28837780 | 0.80 | ADRA2A (0.39) | LMNAEGLN1ALKBH5SUCNR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4320110-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | Universität Basel (CH) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022214701-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2022-10-13 | — | — | WO | disclosed |
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | LMNA 3776/4885EGLN1 2090/4885ALKBH5 3403/4885 |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R1, PIK3R2 | LMNA 4234/4885EGLN1 3566/4885ALKBH5 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.